The association between automatic generic substitution and treatment persistence with oral bisphosphonates

Osteoporosis International

Volumn 23, Issue 8, 2012, Pages 2201-2208

  Strom O ^a   Landfeldt, E ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b OptumInsight   (Sweden)

Author keywords

Adherence; Osteoporosis; Pharmacoepidemiology; Policy; Prescribing; Sweden

Indexed keywords

ALENDRONIC ACID; GENERIC DRUG; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; NONPARAMETRIC TEST; PARAMETRIC TEST; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; REGISTER; SURVIVAL; SWEDEN;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG SUBSTITUTION; DRUGS, GENERIC; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; OSTEOPOROSIS; RETROSPECTIVE STUDIES; SWEDEN; TIME FACTORS;

EID: 84864868835     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1850-4     Document Type: Article

References (29)

1. OECD, Statistics from A to Z (available from: http://www.oecd. org/document/0,3746,en-2649-201185-46462759-1-1-1-1,00.html (accessed June 20, 2011)).
2. Aalto-Setala V (2008) The impact of generic substitution on price competition in Finland. Eur J Health Econ 9(2):185-91
3. Andersson KA, Petzold MG, Allebeck P, Carlsten A (2008) Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five years. BMC Health Serv Res 8:50
4. Sander JW, Ryvlin P, Stefan H, Booth DR, Bauer J (2010) Generic substitution of antiepileptic drugs. Expert Rev Neurother 10 (12):1887-98
5. WHO, Adhence to long term therapies: evidence for action. 2003 (Available from: http://whqlibdoc.who.int/publications/2003/9241545992.pdf accessed March 5, 2010).
6. Strom O, Borgstrom F, Kanis JA, Jonsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20(1):23-34
7. Socialstyrelsen, Patientsäkerhet vid utbyte av läkemedel på apotek. (Available from: http://www.socialstyrelsen.se/ publikationer2004/2004-103-14 (accessed June 10, 2011)).
8. Duerden MG, Hughes DA (2010) Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol 70(3):335-41
9. Heikkila R, Mantyselka P, Ahonen R (2011) Do people regard cheaper medicines effectivě Population survey on public opinion of generic substitution in Finland. Pharmacoepidemiol Drug Saf 20(2):185-91
10. The Swedish Medical Products Agency (2007) behandling av osteoporos 18:19-38
11. TLV, The Dental and Pharmaceutical Benefits Agency. (Available from: http://www.tlv.se accessed April 8, 2011).
12. SCB, Statistics Sweden. (Available from: http://www.scb.se accessed April 10, 2011).
13. Socialstyrelsen (Available from: http://www.socialstyrelsen.se/register accessed April 23, 2011).
14. Landfeldt, E., O. Strom, S. Robbins, and F. Borgstrom, Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA). Osteoporos Int, 2011.
15. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130-9
16. TLV, The Dental and Pharmaceutical Benefits Agency: Översyn av 2011 års modell för utbyte av läkemedel på apotek. 2011 (Available from: www.tlv.se accessed Oct 5, 2011).
17. Landfeldt E, Lundkvist J, Strom O (2011) The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 48 (2):380-8
18. Blouin J, Dragomir A, Ste-Marie LG, Fernandes JC, Perreault S (2007) Discontinuation of antiresorptive therapies: a comparisonbetween 1998-2001 and 2002-2004 among osteoporotic women. J Clin Endocrinol Metab 92(3):887-94
19. Sheehy O, Kindundu CM, Barbeau M, LeLorier J (2009) Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int 20(8):1369-76
20. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W (2006) The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28(10):1686-94
21. Strom, O., F. Borgstrom, J. Kanis, J. Compston, C. Cooper, E. McCloskey, and B. Jonsson, Osteoporosis: burden, health care provision and opportunities in the European Union. Archives of osteoporosis, 2011. E-pub ahead of print.
22. European Commission. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. (Available from: http://www.easp.es/web/ Documentos/OtrosDocumentos/EASPReportPandREurope.pdf accessed July 2, 2011).
23. Himmel W, Simmenroth-Nayda A, Niebling W, Ledig T, Jansen RD, Kochen MM, Gleiter CH, Hummers-Pradier E (2005) What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther 43(10):472-9
24. Horne R, Weinman J (1999) Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47(6):555-67
25. Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK (2011) Physician perceptions about generic drugs. Ann Pharmacother 45(1):31-8
26. Andersson K, Jorgensen T, Carlsten A (2006) Physicians' opinions and experiences of the Pharmaceutical Benefits Reform. Scand J Public Health 34(6):654-9
27. Shakweh M, Bravo-Osuna I, Ponchel G (2007) Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate. Eur J Pharm Sci 31(5):262-70
28. Grima DT, Papaioannou A, Airia P, Ioannidis G, Adachi JD (2010) Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. BMC Musculoskelet Disord 11:68
29. Halkin H, Dushenat M, Silverman B, Shalev V, Loebstein R, Lomnicky Y, Friedman N (2007) Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother 41(1):29-34